InflaRx (NASDAQ:IFRX) Stock Rating Upgraded by Lifesci Capital

InflaRx (NASDAQ:IFRX – Get Rating) was upgraded by research analysts at Lifesci Capital from a “market perform” rating to an “outperform” rating in a research note issued to investors on Wednesday, Benzinga reports. Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of InflaRx in a research note on […]

Related Keywords

Germany ,Nicolas Fulpius ,Niels Christoph Riedemann ,Renfeng Guo ,Kestra Advisory Services ,Virtu Financial ,Jpmorgan Chase Co ,Raymond James Associates ,Group One Trading ,Get Rating ,Lifesci Capital ,Advisory Services ,Raymond James ,Inflarx Daily ,Inflarx ,Nasdaq Ifrx ,Ifrx ,Medical ,Upgrade ,